TG Therapeutics Shares Surge on Robust BRIUMVI Sales and Strong 2026 Guidance

Key Facts

1U.S. BRIUMVI sales reached $594 million in 2025, a 90% year-over-year increase.

2The company guides for 2026 sales to be between $825 million and $850 million.

3Upcoming catalysts include Phase 3 ENHANCE study results and the development of a subcutaneous version of the drug.

TG Therapeutics (TGTX) continues to demonstrate significant momentum as sales for its Multiple Sclerosis treatment, BRIUMVI, reached $594 million in the U.S. during 2025. This performance represents a substantial 90% year-over-year increase, highlighting rapid market adoption and robust demand. Looking ahead, the company has issued optimistic guidance for 2026, forecasting revenues between $825 million and $850 million. Investors are also focused on upcoming clinical milestones, including the Phase 3 ENHANCE study results and the development of a subcutaneous version of the drug. These advancements could further expand the company's competitive edge and market share. Consequently, analysts maintain a 'Strong Buy' rating based on this consistent growth trajectory and promising clinical pipeline.